- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: HBI-8000, CS-055 中文名稱:西達本胺
Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩爾濃度抑制劑,IC50分別為95、160、67、78 nM。
Tucidinostat (Chidamide) Chemical Structure
CAS: 1616493-44-7
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
U2OS | Function assay | 1 uM | 24 hrs | Activation of PPARG (unknown origin) expressed in human U2OS cells at 1 uM in presence of 10 uM rosiglitazone incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of ERbeta (unknown origin) expressed in human U2OS cells at 1 uM in presence of 0.01 uM E2 incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of glulcocorticoid receptor (unknown origin) expressed in human U2OS cells at 1 uM in presence of 0.1 uM dexamethasone incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of ERalpha (unknown origin) expressed in human U2OS cells at 1 uM in presence of 0.01 uM E2 incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of glulcocorticoid receptor (unknown origin) expressed in human U2OS cells at 1 uM incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of PPARG (unknown origin) expressed in human U2OS cells at 1 uM incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of ERalpha (unknown origin) expressed in human U2OS cells at 1 uM incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
U2OS | Function assay | 1 uM | 24 hrs | Activation of ERbeta (unknown origin) expressed in human U2OS cells at 1 uM incubated for 24 hrs by luciferase reporter gene assay | ChEMBL |
Sf9 | Function assay | 5 mins | Inhibition of recombinant human full length HDAC1 expressed in baculovirus infected Sf9 insect cells using biotinylated lysine 9 acetylated histone H3 (1 to 21 residues) as substrate incubated for 5 mins followed by substrate addition measured after 60 mi, IC50 = 0.112 μM. | 28835797 | |
EBC1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay, IC50 = 2.9 μM. | 28835797 | |
HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay, IC50 = 7.8 μM. | 28835797 | |
HL60 | Growth inhibition assay | 48 hrs | Growth inhibition of human HL60 cells incubated for 48 hrs by MTS method, GI50 = 0.4 μM. | ChEMBL | |
Jurkat | Growth inhibition assay | 48 hrs | Growth inhibition of human Jurkat cells incubated for 48 hrs by MTS method, GI50 = 1.5 μM. | ChEMBL | |
U2OS | Growth inhibition assay | 48 hrs | Growth inhibition of human U2OS cells incubated for 48 hrs by MTS method, GI50 = 2 μM. | ChEMBL | |
HepG2 | Growth inhibition assay | 48 hrs | Growth inhibition of human HepG2 cells incubated for 48 hrs by MTS method, GI50 = 4 μM. | ChEMBL | |
LNCAP | Growth inhibition assay | 48 hrs | Growth inhibition of human LNCAP cells incubated for 48 hrs by MTS method, GI50 = 4 μM. | ChEMBL | |
Raji | Growth inhibition assay | 48 hrs | Growth inhibition of human Raji cells incubated for 48 hrs by MTS method, GI50 = 4 μM. | ChEMBL | |
MCF7 | Growth inhibition assay | 48 hrs | Growth inhibition of human MCF7 cells incubated for 48 hrs by MTS method, GI50 = 5 μM. | ChEMBL | |
28SC | Growth inhibition assay | 48 hrs | Growth inhibition of human 28SC cells incubated for 48 hrs by MTS method, GI50 = 5.8 μM. | ChEMBL | |
PANC1 | Growth inhibition assay | 48 hrs | Growth inhibition of human PANC1 cells incubated for 48 hrs by MTS method, GI50 = 6.3 μM. | ChEMBL | |
HeLa | Function assay | 10 mins | Inhibition of HDAC enzymatic activity in human HeLa cells incubated for 10 mins in presence of substrate by colorimetric activity assay, IC50 = 7.2 μM. | ChEMBL | |
MDA-MB-231 | Growth inhibition assay | 48 hrs | Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by MTS method, GI50 = 7.9 μM. | ChEMBL | |
SMMC7721 | Growth inhibition assay | 48 hrs | Growth inhibition of human SMMC7721 cells incubated for 48 hrs by MTS method, GI50 = 16 μM. | ChEMBL | |
DU145 | Growth inhibition assay | 48 hrs | Growth inhibition of human DU145 cells incubated for 48 hrs by MTS method, GI50 = 25 μM. | ChEMBL | |
HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells incubated for 48 hrs by MTS method, GI50 = 40 μM. | ChEMBL | |
hematopoietic malignant cells | Cytotoxicity assay | Cytotoxicity against human hematopoietic malignant cells assessed as growth inhibition, GI50 = 1.86 μM. | ChEMBL | ||
human solid tumor cells | Cytotoxicity assay | Cytotoxicity against human solid tumor cells assessed as growth inhibition, GI50 = 6.65 μM. | ChEMBL | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩爾濃度抑制劑,IC50分別為95、160、67、78 nM。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Chidamide抑制I型HDACs 1-3,以及IIb型HDAC10。在人類宮頸腺癌Hela細胞和人源PBMC細胞中,Chidamide顯著地誘導(dǎo)組蛋白H3乙酰化。在人胚腎(CCC-HEK)和人胚肝(CCC-HEL)中,Chidamide對正常細胞的毒性作用比MS-275大大減少,說明Chidamide對正常細胞和癌細胞的細胞毒性作用的差異[1]。 |
|||
---|---|---|---|---|
細胞實驗 | 細胞系 | PBMC效應(yīng)細胞 | ||
濃度 | 0-400 nM | |||
孵育時間 | 24-72 h | |||
方法 | 將分離的PBMC效應(yīng)細胞接種于6孔板(細胞密度為6 x 106 cells/孔),用不同濃度的chidamide(0-400 nM)處理細胞一定時間(24-72 h)。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | HDAC1 / HDAC2 / HDAC3 / acetyl-H3 / acetyl-H4 Mcl-1 / Myc / Bcl-xl / p21 / p27 / CDK6 / CDK4 / Cyclin D2 Ace-H3K18 / Ace-H3K9 / Ac-H4K8 p-EGFR / EGFR / p-STAT3 / STAT3 / p-AKT / AKT / p-AMPK / MAPK PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 |
![]() |
31289512 | |
Growth inhibition assay | Cell viability |
![]() |
29100410 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | 在小鼠結(jié)腸癌HCT-8移植瘤模型中,Chidamide具有體內(nèi)抗腫瘤活性。給藥濃度范圍為12.5-50 mg/kg的Chidamide可濃度依賴性地減少腫瘤大小和重量。Chidamide的給藥濃度為50 mg/kg時,相較于對照藥物組5-FU(20 mg/kg)和MS-275組(25 mg/kg)具有相似甚至更大的功效。在攜瘤動物模型中,Chidamide耐受良好[1]。 |
|
---|---|---|
動物實驗 | Animal Models | Athymic nude mice (BALB/c-nu) |
Dosages | 12.5-50 mg/kg | |
Administration | oral |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT05586841 | Not yet recruiting | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
November 1 2022 | Phase 1 |
NCT05141357 | Terminated | Non Small Cell Lung Cancer |
HUYABIO International LLC. |
March 14 2022 | Phase 2 |
NCT04994210 | Recruiting | Safety and Efficacy |
Sun Yat-sen University |
October 4 2021 | Phase 2 |
NCT05140616 | Recruiting | Safety and Efficacy |
The First Affiliated Hospital of Soochow University |
May 31 2021 | Phase 1|Phase 2 |
NCT04651127 | Unknown status | Cervical Cancer|Cervix Cancer|Cervix Neoplasm |
Sun Yat-sen University |
November 9 2020 | Phase 1|Phase 2 |
分子量 | 390.41 | 分子式 | C22H19FN4O2 |
CAS號 | 1616493-44-7 | SDF | Download Tucidinostat (Chidamide) SDF |
Smiles | C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 78 mg/mL ( (199.78 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Ethanol : 1 mg/mL (2.56 mM) Water : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項